Upadacitinib with glucocorticoids superior to glucocorticoids alone for giant cell arteritis remission
1. In this randomized trial, upadacitinib dosed at 15mg with a 26-week glucocorticoid taper showed superior efficacy than placebo with ...
Tag: upadacitinib
Upadacitinib therapy effective at inducing remission in Crohn’s disease
1. In this randomized controlled trial, upadacitinib resulted in higher remission rates for patients with Crohn’s disease compared to a ...
Upadacitinib is safe and effective in adolescents with moderate-to-severe atopic dermatitis
1. Upadacitinib, a new once-daily oral systemic medication, reduces eczema severity and improves clinician- and patient-reported measures in adolescents with ...
Bimekizumab is effective for active psoriatic arthritis in biologic-naïve adults
1. Significantly more patients in the bimekizumab group reached ACR50 at week 16 compared to the placebo. 2. Fungal infections ...
Upadacitinib is safe and effective for treatment of non-radiographic axial spondyloarthritis
1. Significantly more patients in the upadacitinib group achieved ASAS40 response at week 14 compared to the placebo group. 2. ...
Upadacitinib significantly improves clinical remission rate for moderately to severely active ulcerative colitis
1. Upadacitinib led to significantly greater percentages of clinical remission compared to placebo for both induction and maintenance studies. 2. ...
#VisualAbstract: Upadacitinib plus topical corticosteroids is safe and effective for moderate-to-severe atopic dermatitis;
1. Upadacitinib combined with topical corticosteroids reduced Eczema Area and Severity Index (EASI) and Investigator’s Global Assessment for atopic dermatitis ...
Upadacitinib plus topical corticosteroids is safe and effective for moderate-to-severe atopic dermatitis
1. Upadacitinib combined with topical corticosteroids reduced Eczema Area and Severity Index (EASI) and Investigator’s Global Assessment for atopic dermatitis ...
Upadacitinib monotherapy is effective for patients with moderate-to-severe atopic dermatitis
1. The proportion of patients with EASI ≥75% was significantly greater in the upadacitinib 30 mg and 15 mg groups ...
Upadacitinib non-inferior to adalimumab for psoriatic arthritis treatment
1. Janus kinase (JAK) inhibitor upadacitinib showed non-inferior efficacy in improving psoriatic arthritis compared to standard-of-care adalimumab. 2. High-dose upadacitinib ...